NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has increased by 3.1% and is now trading at $88.54. View which stocks have been mosted impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences.

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Neurocrine Biosciences.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Tuesday, February, 4th. The company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.75 by $0.40. The company earned $244.10 million during the quarter, compared to analysts' expectations of $231.54 million. Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The company's revenue for the quarter was up 85.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. View Neurocrine Biosciences' earnings history.

16 brokerages have issued 1-year price targets for Neurocrine Biosciences' shares. Their forecasts range from $88.00 to $153.00. On average, they expect Neurocrine Biosciences' stock price to reach $117.07 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View analysts' price targets for Neurocrine Biosciences.

News coverage about NBIX stock has been trending extremely negative this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNeurocrine Biosciences.

Neurocrine Biosciences saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 4,930,000 shares, an increase of 13.6% from the February 13th total of 4,340,000 shares. Based on an average daily volume of 825,600 shares, the days-to-cover ratio is presently 6.0 days. Approximately 5.4% of the shares of the stock are short sold. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Netflix (NFLX), Gilead Sciences (GILD), salesforce.com (CRM), Twilio (TWLO), Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%) and Geode Capital Management LLC (1.12%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P., and Nuveen Asset Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, and Matt Abernethy. View insider buying and selling activity for Neurocrine Biosciences.

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, 1832 Asset Management L.P., and Swiss National Bank. View insider buying and selling activity for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $88.54.

Neurocrine Biosciences has a market capitalization of $8.17 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. View additional information about Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]